Illumina introduces Billion Cell Atlas to accelerate AI and drug discovery
The Atlas will enable the validation of genetic targets and training of AI models at unprecedented scale Illumina, Inc. (NASDAQ: ILMN) today introduced the world’s largest genome-wide genetic perturbation dataset, being built to accelerate drug discovery through AI across the pharmaceutical ecosystem. The Illumina Billion Cell Atlas is the first tranche of its program to build…
